International Flavors & Fragrances Inc. (IFF) Overview
IFF is one of the world's "big four" flavour-and-fragrance houses and, following the 2021 merger with DuPont Nutrition & Biosciences, the broadest specialty-ingredients platform in consumer goods. The company is now in the final phase of a multi-year portfolio simplification: having divested 13 non-core businesses for roughly US$10bn of gross proceeds, it agreed in May 2026 to sell its largest and lowest-margin unit, Food Ingredients, to CVC Capital Partners for an enterprise value of ~US$4.3bn. The go-forward company comprises three innovation-led segments — Taste, Scent and Health & Biosciences — guided to ~US$7.4–7.6bn of 2026 sales at a ~21% adjusted operating EBITDA margin, with leading positions in flavours, fine and consumer fragrance, enzymes, cultures and probiotics. The investment debate centres on whether the slimmer, higher-margin IFF can re-rate towards Givaudan-like multiples once deleveraging, a US$2.5bn buyback and resolution of the global fragrance antitrust investigations are delivered.
What the company does
IFF designs, manufactures and sells proprietary ingredient systems that determine how consumer products taste, smell, feel and perform. Its products are almost never visible to the end consumer: they are formulated into customers' beverages, dairy products, snacks, savoury foods, sweets, dietary supplements, perfumes, detergents, shampoos, home-care products, animal feed, biofuels and industrial processes.
The company's own boilerplate (2026) describes IFF as a business that "makes joy through science, creativity and heart" and positions itself as the global leader in flavours, fragrances, and health and biosciences — a description that, notably, dropped the words "food ingredients" between the February 2026 and August 2026 releases, mirroring the decision to divest that segment.
Business model
Co-creation and formulation model (Taste, Scent): IFF wins "briefs" from consumer-goods customers and creates bespoke, confidential formulas (flavour compounds, fragrance compounds). Once a formula is adopted into a customer's product it typically remains for the product's lifecycle, producing recurring, annuity-like revenue. Switching costs are high because reformulation risks consumer rejection. Many large customers operate "core lists" of a small number of approved suppliers, which is a structural barrier to entry.
Science-platform model (Health & Biosciences): Revenue derives from proprietary enzymes, cultures, probiotics and biotech-derived ingredients produced through fermentation. Value is underpinned by strain libraries, protein-engineering IP and large-scale fermentation capacity (the DuPont/Genencor/Danisco heritage).
- Ingredient-supply model (Fragrance Ingredients and, until divested, Food Ingredients). More volume-driven, partly commodity-exposed businesses (aroma chemicals; texturants, emulsifiers, plant proteins).
Revenue model mix
| Revenue type | Estimated share | Basis |
|---|---|---|
| Product sales (compounds, ingredients, enzymes, cultures) | ~100% | 10-K revenue recognition; services embedded |
| Services billed separately | Not material / not publicly disclosed | — |
| Licensing / royalties | Not material / not publicly disclosed | — |
IFF is overwhelmingly a product company: revenue is recognised on shipment of physical ingredients. Formulation, sensory and application services are bundled into product pricing rather than billed separately. There is no material subscription or licensing revenue disclosed. A small portion of H&B revenue derives from technology collaborations, but this is not separately quantified (not publicly disclosed).
Value-chain position
IFF sits in the middle of the chain: upstream it buys natural raw materials (citrus oils, vanilla, botanicals, crude sulphate turpentine, petrochemical intermediates, agricultural commodities, sugars for fermentation) and downstream it sells to brand owners and contract manufacturers. Value capture comes from formulation know-how, regulatory dossiers, application labs and fermentation IP rather than from raw-material processing.
Customer types and end-markets
| Customer type | Examples of end use | Primary IFF segment |
|---|---|---|
| Global food & beverage multinationals | Soft drinks, dairy, savoury, sweet goods | Taste; (Food Ingredients — divesting) |
| Regional/local food & beverage manufacturers | Local beverages, bakery, snacks | Taste |
| Fine-fragrance houses and luxury/prestige brands | Perfumes, eau de toilette | Scent (Fine Fragrance) |
| Home & personal-care multinationals | Detergents, fabric care, shampoo, soap | Scent (Consumer Fragrance); H&B (Home & Personal Care enzymes) |
| Dietary-supplement and infant-nutrition companies | Probiotics, HMOs | H&B (Health) |
| Animal-nutrition and feed producers | Feed enzymes (phytase), probiotics | H&B (Animal Nutrition) |
| Grain processors and biofuel producers | Ethanol, starch, sweetener processing | H&B (Grain Processing) |
| Pharmaceutical manufacturers | Excipients (until 2025 disposal) | Pharma Solutions (divested May 2025) |
Independent characterisation
IFF is best understood today as a company in transition from a sprawling, leverage-burdened conglomerate (post-Frutarom and DuPont N&B) to a focused "taste-scent-biosciences" pure play. On a continuing-operations basis it generated a 21.8% adjusted operating EBITDA margin in H1 2026, versus 19.2% for the full 2025 portfolio — the arithmetic of the portfolio change is margin-accretive, but the company will be roughly one-third smaller by revenue than it was in 2024. Its closest strategic analogue is Givaudan, which has historically commanded a significant valuation premium; the core thesis of the turnaround is closing that gap.
Strategy
Stated strategy (themes from 2025–2026 filings and releases)
-
Portfolio focus on three innovation-led pillars — Taste, Scent and Health & Biosciences. Management describes the Food Ingredients sale as the step that creates a "simpler, higher-growth, higher-margin company with enhanced cash generation."
-
Business-led operating model. Implemented in 2025 to strengthen accountability, customer focus and decision speed, with emphasis on margin improvement, cash generation and execution consistency (Chair's letter, 2026 Proxy).
-
Reinvestment in R&D, commercial capabilities and capacity (FY2025 R&D US$694m; capex 5.5% of sales).
-
Productivity and cost discipline via the IFF Productivity Program and expanded GBS centres with AI automation.
-
Balance-sheet strength and disciplined capital allocation — leverage target 2.0–2.5x; investment in the business; return of excess capital.
-
Responsible AI adoption — new AI Policy and AI Governance Framework (March 2026), agentic AI embedded in IT, GBS, R&D and Finance.
-
Sustainability ("Do More Good") — four pillars: conscious sourcing, partnerships of impact, intentional innovation, operating for the future.
Strategic initiatives register (last 24 months)
| Date | Initiative | Type | Target / detail |
|---|---|---|---|
| 2024–2026 | IFF Productivity Program | Cost / restructuring | Severance, site closures; FY2025 charge US$70m; H1 2026 US$10m |
| Feb 2025 | Business-led operating model and new ELT | Organisation | Segment presidents own P&Ls |
| 2,025 | Debt tender offers using Pharma proceeds | Deleveraging | US$2.9bn principal repaid in FY2025; US$488m gain |
| Q4 2025 | US$500m share-repurchase authorisation | Capital return | First buyback since merger |
| Q4 2025 | Food Ingredients strategic review / sale process | Portfolio | Concluded with CVC deal |
| Mar 2026 | AI Policy and AI Governance Framework | Technology / governance | Aligned with EU AI Act prohibitions |
| 2,026 | Expanded GBS reorganisation incl. AI | Cost | Customer service, supply chain, logistics |
| May 2026 | Food Ingredients sale to CVC | Portfolio | EV ~US$4.3bn (~10x EBITDA) |
| Jul 2026 | SuanNutra carve-out | Portfolio | ~US$170m revenue exited |
| Aug 2026 | Sequenced use-of-proceeds framework | Capital allocation | >US$1bn debt reduction; US$2.5bn buyback by end-2027 |
| Aug 2026 | Stranded-cost remediation | Cost | ~US$100m stranded costs; ~two-thirds eliminated within 12 months of close, substantially all within 24 months |
| 2,026 | AQUASCENT™, Omni-Bos™ PHY launches; Brazil enzyme centre | Innovation / footprint | See Section 13 |
Management targets and guidance
| Metric | FY2026 guidance (original, 11 Feb 2026; total company) | FY2026 guidance (4 Aug 2026; continuing operations) |
|---|---|---|
| Net sales | US$10.5–10.8bn | US$7.4–7.6bn (excl. ~US$3.2bn discontinued) |
| Adjusted operating EBITDA | US$2.05–2.15bn | US$1.53–1.60bn (excl. ~US$520m discontinued) |
| Comparable currency-neutral sales growth | 1–4% | 2–4% |
| Comparable currency-neutral adj. EBITDA growth | 3–8% | 4–8% |
| FX impact | ~+1% sales; ~0% EBITDA | ~+1% sales; ~+2% EBITDA |
| Divestiture impact | ~−5% to both sales and EBITDA | Embedded in continuing basis |
| Leverage target | — | 2.0–2.5x net debt/EBITDA |
Products & Services
IFF does not publish a priced catalogue; pricing is bespoke and contract-based (not publicly disclosed). The catalogue below is organised by segment and lists named platforms and recently launched offerings identified in company releases. Launch years are given where disclosed; otherwise "NA".
Taste
| Offering | Description / capabilities | Target customer | Launch / latest | Notes |
|---|---|---|---|---|
| Flavour compounds (beverage) | Custom flavour systems for carbonated soft drinks, juices, RTD tea/coffee, alcoholic beverages | Beverage multinationals and regional bottlers | Ongoing | Core of Taste |
| Flavour compounds (sweet & dairy) | Vanilla, fruit, dairy and confectionery profiles; dairy-specific taste solutions | Dairy, bakery, confectionery | Ongoing | IFF published "Dear Dairy: The Life Stages Guide" consumer-insight resource (2026) |
| Flavour compounds (savoury) | Savoury, snack seasoning and meat-alternative flavours | Snack, prepared-food and plant-based brands | Ongoing | Savoury Solutions business itself sold to PAI (2023) |
| Taste modulation / sugar & salt reduction | Sweetness enhancers, masking agents, mouthfeel modifiers | Reformulating F&B brands | Ongoing | Benefits from GLP-1 and health-driven reformulation |
| Natural flavours | Natural-origin extracts and flavour preparations | Clean-label brands | Ongoing | Some Peru-based localised flavour activities sold to SuanNutra (2026) |
| Designed/consumer-insight services | Sensory science, consumer insight, application labs | All Taste customers | Ongoing | Bundled, not separately billed |
Scent
| Offering | Description / capabilities | Target customer | Launch / latest | Notes |
|---|---|---|---|---|
| Fine Fragrance | Perfumer-created fragrances for prestige, mass-prestige and niche brands | Luxury houses, celebrity and niche brands | Ongoing | Double-digit growth in FY2025; low-single-digit in Q2 2026 owing to the Middle East conflict |
| AQUASCENT™ | Vegan, water-based (alcohol-free) carrier for fine fragrance using biodegradable materials; improved olfactive performance and clarity; shipping benefits | Fine-fragrance brands | 2,026 | New scent-technology platform |
| Consumer Fragrance | Fragrances for fabric care, home care, personal wash, hair care, toiletries | Home & personal-care multinationals | Ongoing | High-single-digit growth in Q2 2026 |
| Fragrance Ingredients | Aroma chemicals and specialty molecules (captive and merchant sales) | Fragrance houses, compounders | Ongoing | Double-digit growth in Q2 2026 after FY2025 commodity declines |
| LMR Naturals by IFF | Natural raw materials for perfumery, cosmetics and flavours (Grasse, France) | Perfumers, cosmetic brands | Ongoing | Showcased at SIMPPAR 2026 |
| Encapsulation / delivery systems | Fragrance-release technologies for longevity in detergents and personal care | Consumer-goods majors | Ongoing | — |
| CitraSource | Citrus-based ingredients | Flavour and fragrance users | Held for sale (2026) | US$27m loss on assets held for sale booked Q2 2026 |
Health & Biosciences
| Offering | Description / capabilities | Target customer | Launch / latest | Notes |
|---|---|---|---|---|
| Probiotics (incl. HOWARU® heritage line) | Clinically studied probiotic strains for supplements and foods | Supplement and infant-nutrition brands | Ongoing | Brand naming per DuPont heritage (confirm current branding) |
| Human milk oligosaccharides (HMOs) | Infant-nutrition prebiotics | Infant-formula makers | Ongoing | Health business; North America softness in Q4 2025 |
| Food cultures & food enzymes | Dairy cultures, bakery and brewing enzymes, bioprotection | Dairy, bakery, beverage processors | Ongoing | Food Biosciences grew high-single-digit in FY2025 |
| Home & Personal Care enzymes | Proteases, amylases, lipases for detergents; biopolymers | Detergent manufacturers | Ongoing | Mid-to-high single-digit growth FY2025 |
| Omni-Bos™ PHY | Novel phytase enzyme for dairy cattle improving nutrient utilisation and feed efficiency | Dairy producers/feed integrators | 2026 (MEA and APAC first) | Animal Nutrition innovation |
| Feed enzymes & probiotics (Animal Nutrition) | Phytases, xylanases, direct-fed microbials | Feed producers | Ongoing | Double-digit growth in Q4 2025 |
| Grain Processing enzymes | Enzymes for fuel ethanol, starch, sweetener processing | Ethanol producers, wet millers | Ongoing | Led H&B growth in Q2 2026 |
| Brazil enzyme centre & application lab | Latin American enzyme hub and application laboratory | LatAm customers | 2,026 | Expands regional footprint |
Food Ingredients (discontinued; pending sale to CVC)
| Offering | Description | Status |
|---|---|---|
| Texturants | Hydrocolloids (pectin, carrageenan, alginates, cellulosics for food) | Transferring to CVC |
| Emulsifiers & Sweeteners | Emulsifiers and sweetening systems | Transferring to CVC |
| Protein Solutions / plant-based | Plant proteins and systems | Transferring to CVC |
| Systems & Inclusions | Integrated ingredient systems; inclusions (fruit preparations, pieces) | Transferring to CVC; Inclusions grew double-digit in FY2025 |
| Soy Crush, Concentrates & Lecithin | Soy processing and lecithin | Sold to Bunge, 2 Mar 2026 |
Natural specialties being sold to SuanNutra (agreement July 2026)
| Offering | Description | Status |
|---|---|---|
| Botanical extracts | Clinically supported branded botanical ingredients (e.g., olive-leaf extract) | Sale expected to close by end-2026 |
| Vitamins & minerals | Fermented vitamins and minerals | As above |
| Food enhancement / natural colours / antioxidants | Natural colours, antioxidants, natural betaine | As above |
| Localised flavour activities (Peru) | Select flavour operations | As above |
Combined revenue ~US$170m (2025), ~600 employees, five manufacturing facilities in Europe, the US and Latin America; terms not disclosed.
Divested: Pharma Solutions (for completeness)
Excipients and functional ingredients for pharmaceuticals and nutraceuticals (sold to Roquette, closed 1 May 2025); nitrocellulose (sold 9 May 2025).
Financial Narrative
H1 2026 figures are on the new continuing-operations basis and are not comparable with full-year columns.
Income statement
Note: the 2026 proxy reports FY2025 diluted EPS of US$(1.41) whereas the results release reports US$(1.46); the discrepancy likely reflects a post-release adjustment in the 10-K (both cited; the 10-K figure should prevail). FY2023 DPS reflects four quarterly payments of US$0.81; the reset to US$0.40 per quarter took effect from Q1 2024.
Revenue CAGR FY2021–FY2025 (reported): (10,890 / 11,656)^(1/4) − 1 ≈ −1.7% p.a., entirely driven by divestitures; comparable currency-neutral growth was positive in FY2024 (~6%, as referenced by management) and FY2025 (+2%).
Commentary. Reported revenue has been flat-to-down since the 2022 peak (US$12.44bn) because IFF has been selling businesses faster than it has grown. Underlying performance improved under Fyrwald: comparable currency-neutral adjusted EBITDA grew 7% in FY2025 on just 2% organic sales growth, reflecting productivity programmes. GAAP earnings remain noisy. FY2025's operating loss was caused by a US$1,153m goodwill impairment in the Food Ingredients reporting unit (the market-implied value revealed by the sale process), partially offset below the operating line by a US$488m gain on debt extinguishment (bonds repurchased below par via tender offers). Recurring below-the-line charges include regulatory costs of US$106m in FY2025 (legal fees and provisions for the fragrance investigations) and divestiture costs of US$125m.
Balance sheet
H1 2026 (30 June 2026, continuing/discontinued presentation): cash US$569m; total assets US$25,154m; goodwill & intangibles (continuing) US$11,877m; current assets of discontinued operations US$4,840m; short-term borrowings US$964m; long-term debt US$4,735m; total debt US$5,735m; net debt US$5,166m; equity US$14,009m.
Commentary. The balance sheet has been transformed by disposals. Long-term debt fell by ~US$2.8bn in FY2025 as Pharma Solutions proceeds (~US$2.7bn net received in H1 2025) funded tender offers. Net debt to credit-adjusted EBITDA fell from ~3.8x at end-2024 to 2.6x at end-2025 and 2.5x at 30 June 2026, against a covenant maximum of 3.75x. Goodwill and intangibles still represent ~56% of total assets, a legacy of the Frutarom and DuPont N&B transactions, which keeps impairment risk elevated. Management targets 2.0–2.5x net debt/EBITDA and plans >US$1bn of further debt reduction from CVC proceeds.
Cash flow
H1 2026 (incl. discontinued operations): CFO US$679m (+US$311m y/y); capex US$301m; FCF US$378m (+US$284m y/y); dividends US$204m; treasury purchases US$71m; net commercial-paper repayment US$264m; disposal proceeds US$201m.
Commentary. FY2025 free cash flow (US$256m) was weak because capex rose to ~5.5% of sales (capacity expansion and reinvestment) while operating cash flow fell on lower incentive-accrual timing and working capital. H1 2026 shows a sharp recovery, driven by payables (+US$288m) and lower incentive payouts. Management has flagged up to ~US$100m of H2 2026 working-capital headwind from the Food Ingredients separation (unwinding of factoring arrangements and inventory builds).
Ratios
Ratios computed by the analyst from reported figures; FY2024 net debt/EBITDA of ~3.8x is as stated in the 2026 proxy. Days payables were not disclosed separately in the condensed balance sheet, so a full cash conversion cycle is NA. ROIC is not disclosed by the company and is not estimated. The deterioration in DIO to ~118 days is notable and consistent with management's focus on working-capital release.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Reportable Segments by Period
| Period | Reportable segments | Notes |
|---|---|---|
FY2021–FY2023 | Nourish; Scent; Health & Biosciences; Pharma Solutions | Post-DuPont N&B structure |
FY2024–FY2025 | Taste; Food Ingredients; Health & Biosciences; Scent; Pharma Solutions | Nourish split into Taste and Food Ingredients (business-unit reorganisation, 2024). Pharma Solutions sold 1 May 2025 |
From Q2 2026 (continuing operations) | Taste; Health & Biosciences; Scent | Food Ingredients disposal group and SCL disposal group reported as discontinued operations, with comparatives recast |
Segment Overview
| Segment | Business units / contents | Status |
|---|---|---|
Taste | Flavour compounds for beverages, sweet, savoury, dairy; taste-modulation and sugar/salt-reduction systems; natural flavours | Continuing |
Scent | Fine Fragrance; Consumer Fragrance (fabric care, home care, personal wash, hair care); Fragrance Ingredients (aroma chemicals, naturals incl. LMR Naturals); CitraSource (citrus; classified held for sale in 2026) | Continuing (CitraSource being exited) |
Health & Biosciences | Health (probiotics, HMOs, dietary-supplement actives); Food Biosciences (cultures, food enzymes); Home & Personal Care (detergent enzymes, biopolymers); Animal Nutrition (feed enzymes, probiotics); Grain Processing (enzymes for ethanol, starch and sweeteners) | Continuing |
Food Ingredients | Texturants, emulsifiers & sweeteners, plant-based proteins (Protein Solutions), systems, inclusions, SCL (sold) | Discontinued; sale to CVC pending |
Pharma Solutions | Excipients (cellulosics, alginates), nitrocellulose | Divested May 2025 |
Segment net sales (USD Mn)
| Segment net sales (USD Mn) | FY2024 | FY2025 |
|---|---|---|
Taste | 2,428 | 2,481 |
Food Ingredients | 3,365 | 3,278 |
Health & Biosciences | 2,203 | 2,283 |
Scent | 2,439 | 2,479 |
Pharma Solutions | 1,049 | 369 |
Total net sales | 11,484 | 10,890 |
Segment adjusted operating EBITDA (USD Mn)
| Segment adjusted operating EBITDA (USD Mn) | FY2024 | FY2025 |
|---|---|---|
Taste | 460 | 478 |
Food Ingredients | 408 | 423 |
Health & Biosciences | 577 | 594 |
Scent | 545 | 515 |
Pharma Solutions | 215 | 76 |
Total adjusted operating EBITDA | 2,205 | 2,086 |
Segment adjusted operating EBITDA margin (%)
| Segment adjusted operating EBITDA margin (%) | FY2024 | FY2025 |
|---|---|---|
Taste | 18.9 | 19.3 |
Food Ingredients | 12.1 | 12.9 |
Health & Biosciences | 26.2 | 26.0 |
Scent | 22.3 | 20.8 |
Pharma Solutions | 20.5 | 20.6 |
Consolidated | 19.2 | 19.2 |
Segment Revenue
| Segment | Reported sales growth FY2025 (%) | Comparable currency-neutral sales growth (%) | Comparable currency-neutral adj. EBITDA growth (%) | % of FY2025 sales |
|---|---|---|---|---|
Taste | 2 | 4 | 10 | 22.8 |
Food Ingredients | -3 | -3 | 10 | 30.1 |
Health & Biosciences | 4 | 3 | 7 | 21.0 |
Scent | 2 | 3 | 2 | 22.8 |
Pharma Solutions | -65 | 12 | 16 | 3.4 |
Consolidated | -5 | 2 | 7 | 100.0 |
Continuing ops net sales (USD Mn)
| Continuing ops net sales (USD Mn) | H1 2025 | H1 2026 |
|---|---|---|
Taste | 1,304 | 1,368 |
Health & Biosciences | 1,079 | 1,176 |
Scent | 1,217 | 1,316 |
Pharma Solutions | 369 | 0 |
Total continuing ops | 3,969 | 3,860 |
Continuing ops adjusted operating EBITDA (USD Mn)
| Continuing ops adjusted operating EBITDA (USD Mn) | H1 2025 | H1 2026 |
|---|---|---|
Taste | 246 | 276 |
Health & Biosciences | 262 | 290 |
Scent | 259 | 275 |
Pharma Solutions | 76 | 0 |
Total | 843 | 841 |
Continuing ops adj. EBITDA margin (%)
| Continuing ops adj. EBITDA margin (%) | H1 2025 | H1 2026 |
|---|---|---|
Taste | 18.9 | 20.2 |
Health & Biosciences | 24.3 | 24.7 |
Scent | 21.3 | 20.9 |
Consolidated | 21.2 | 21.8 |
Q2 2026 Segment Details
| Q2 2026 segment | Reported sales (USD Mn) | Reported growth (%) | Comparable currency-neutral sales growth (%) | Adj. EBITDA (USD Mn) | Margin (%) |
|---|---|---|---|---|---|
Taste | 688 | 5 | 4 | 124 | 18.0 |
Health & Biosciences | 601 | 8 | 5 | 150 | 25.0 |
Scent | 665 | 10 | 8 | 134 | 20.2 |
Consolidated (continuing) | 1,954 | 2 | 6 | 408 | 20.9 |
Income statement (USD Mn)
| Income statement (USD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Net sales | 11,656 | 12,440 | 11,479 | 11,484 | 10,890 |
Cost of sales | — | — | — | 7,360 | 6,952 |
Gross profit | — | — | — | 4,124 | 3,938 |
Research & development expense | — | — | — | 671 | 694 |
Selling & administrative expense | — | — | — | 1,995 | 1,834 |
Amortisation of acquisition intangibles | — | — | — | 610 | 568 |
Goodwill impairment | — | — | — | 64 | 1,153 |
Operating profit (loss) | — | — | — | 766 | -382 |
Interest expense | — | — | — | 305 | 229 |
Income (loss) before taxes | — | — | — | 308 | -412 |
Net income (loss) attributable to IFF | 268 | -1,871 | -2,567 | 263 | -374 |
Adjusted operating EBITDA (non-GAAP) | — | — | — | 2,205 | 2,086 |
EBITDA (GAAP operating profit + D&A) | — | — | — | 1,781 | 580 |
Per share (USD)
| Per share (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Diluted EPS (GAAP) | 1.12 | -7.32 | -10.05 | 1.04 | -1.46 |
Basic EPS (GAAP) | — | — | — | 1.04 | -1.46 |
Adjusted diluted EPS (non-GAAP) | — | — | — | 2.44 | 2.52 |
Adjusted EPS ex amortisation (non-GAAP) | — | — | — | 4.22 | 4.20 |
Dividends declared per share | — | — | 3.24 | 1.60 | 1.60 |
Margins (%)
| Margins (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin | — | — | — | 35.9 | 36.2 |
Operating margin (GAAP) | — | — | — | 6.7 | -3.5 |
Adjusted operating EBITDA margin | — | — | — | 19.2 | 19.2 |
Net margin (GAAP) | 2.3 | -15.0 | -22.4 | 2.3 | -3.4 |
Balance Sheet
| Balance sheet (USD Mn, year-end) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Cash & cash equivalents | 703 | 469 | 590 |
Receivables, net | — | 1,624 | 1,731 |
Inventories | — | 2,133 | 2,245 |
Assets held for sale | — | 3,056 | 151 |
Total current assets | — | 7,968 | 5,594 |
Property, plant & equipment, net | — | 3,739 | 4,029 |
Goodwill & other intangibles, net | — | 15,520 | 14,312 |
Total assets | — | 28,723 | 25,537 |
Short-term borrowings | — | 1,413 | 1,254 |
Long-term debt | — | 7,564 | 4,740 |
Total debt (incl. finance leases, company definition) | — | — | 6,026 |
Net debt (company definition) | — | — | 5,436 |
Total current liabilities | — | 4,352 | 3,933 |
Shareholders' equity | — | 13,869 | 14,180 |
Working capital (current assets − current liabilities) | — | 3,616 | 1,661 |
Cash flow (USD Mn)
| Cash flow (USD Mn) | FY2024 | FY2025 |
|---|---|---|
Net cash from operating activities | 1,070 | 850 |
Capital expenditures (PP&E) | 463 | 594 |
Free cash flow (CFO − capex) | 607 | 256 |
Dividends paid | 514 | 409 |
Share repurchases (treasury stock) | 0 | 38 |
Net proceeds from business disposals | 875 | 2,743 |
Principal payments of debt | 1,030 | 2,913 |
Depreciation & amortisation | 1,015 | 962 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2024 | FY2025 |
|---|---|---|
ROE (net income / year-end equity, %) | 1.9 | -2.6 |
ROA (net income / year-end total assets, %) | 0.9 | -1.5 |
Current ratio (x) | 1.83 | 1.42 |
Debt / equity (x, borrowings only) | 0.65 | 0.42 |
Net debt / credit-adjusted EBITDA (x, company) | 3.8 | 2.6 |
Adjusted operating EBITDA / interest expense (x) | 7.2 | 9.1 |
GAAP operating profit / interest expense (x) | 2.5 | -1.7 |
Asset turnover (sales / year-end assets, x) | 0.40 | 0.43 |
Days sales outstanding (receivables / sales × 365) | 52 | 58 |
Days inventory outstanding (inventory / COGS × 365) | 106 | 118 |
Geographic net sales (USD Mn)
| Geographic net sales (USD Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total | 11,479 | 11,484 | 10,890 |
Region Overview
| Region | Signal | Source |
|---|---|---|
North America | Taste Q4 2025 growth led by a strong North American performance; H&B Health business soft in North America in Q4 2025 | FY2025 release |
All regions (Taste) | Broad-based growth in all regions in FY2025, Q1 2026 and Q2 2026 | FY2025 and Q2 2026 releases |
Middle East | Fine Fragrance growth slowed to low-single-digits in Q2 2026 owing to the Middle East conflict | Q2 2026 release |
Russia | Food Ingredients lost sales due to Russia sanctions | Q4 2025 earnings call |
Latin America | New enzyme centre and application lab in Brazil (2026) signals investment priority | Company announcement |
Middle East, Africa, APAC | First-launch markets for Omni-Bos™ PHY dairy-cattle phytase | Company announcement |
Market Data Point Details
| Market data point | Value | Date / source |
|---|---|---|
Share price | US$77.53 | Close 10 Jul 2026 (stockanalysis.com) |
Share price | US$74.43 | ~21 May 2026 (Investing.com) |
Share price | US$72.85 | Spring 2026 (Yahoo Finance FR) |
52-week range | US$59.14–84.45 | Yahoo Finance (spring 2026) |
Market capitalisation | ~US$19.8bn | 10 Jul 2026 |
Shares outstanding | ~255.3m | Mid-2026 |
1-year TSR | +1.8% | Boardroom Alpha (May 2026) |
3-year TSR | +1.3% (cumulative/annualised basis not specified) | Boardroom Alpha (May 2026) |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
P/E (adjusted EPS ex amortisation FY2025 US$4.20) | ~18.5x | FY2025 |
EV/EBITDA (total company incl. discontinued) | ~12.0x | EV ≈ US$19.8bn + US$5.17bn net debt ≈ US$25.0bn; ÷ ~US$2.09bn 2026E total adj. EBITDA (midpoint continuing US$1.565bn + ~US$0.52bn discontinued) |
EV/Sales (total company) | ~2.3x | ÷ ~US$10.7bn 2026E total sales |
P/B | ~1.4x | ÷ US$14.0bn equity (30 Jun 2026) |
Valuation history (x) | FY2021 | FY2022 |
Analyst Ratings & Targets
| Broker | Rating | Price target (USD) | Note |
|---|---|---|---|
Benchmark (initiation) | Buy | 100 | Sees FI sale unlocking value |
BofA | Buy | 98 (raised from 92); earlier cut to 92 from 99 after FI deal | Sequence of revisions in 2026 |
Morgan Stanley | Overweight | 95 (from 93) | Higher peer multiples |
JPMorgan | Overweight | 92 (from 90) | — |
Barclays (L. Lieberman) | Overweight | 90 (from 80) | — |
Oppenheimer | Outperform | 90 (from 88) | — |
Citi | Buy | 88 (cut from 96) | — |
Argus | Buy | 85 (from 80) | — |
Zacks | Rank #5 (Strong Sell) | — | Post-Q2 estimate cuts |
Aggregate | ~24 Buy / 8 Hold / 1 Sell | Mean target ~US$91 (Yahoo/Simply Wall St, 2026) | — |
Dividends declared per share (USD)
| Dividends declared per share (USD) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Dividend per share | 3.24 | 1.60 | 1.60 |
Dividends paid (USD Mn)
| Dividends paid (USD Mn) | FY2024 | FY2025 |
|---|---|---|
Cash dividends paid | 514 | 409 |
Authorisation Details
| Authorisation | Date | Size | Status |
|---|---|---|---|
Initial authorisation | Q4 2025 | US$500m | US$38m executed FY2025; US$71m in H1 2026; ~US$400m remaining rolled into new programme |
Enhanced authorisation | 4 Aug 2026 | US$2.5bn total (incl. ~US$400m remaining) | US$500m ASR in H2 2026; US$2.0bn after FI close; completion targeted by end-2027 |
Credit Ratings
| Agency | Rating | Outlook |
|---|---|---|
S&P Global Ratings | BBB (long-term) / A-2 (short-term) | Stable |
Debt component (USD Mn)
| Debt component (USD Mn) | Value |
|---|---|
Short-term borrowings (incl. commercial paper and current maturities) | 964 |
Long-term debt | 4,735 |
Total debt (incl. finance leases) | 5,735 |
Cash & equivalents | 569 |
Net debt | 5,166 |
Credit-adjusted EBITDA (TTM, incl. discontinued) | 2,056 |
Net debt / credit-adjusted EBITDA | 2.5x (covenant maximum 3.75x) |
Analyst Conclusions
Management guidance (continuing operations, FY2026)
| Metric | Guidance |
|---|---|
| Net sales | US$7.4–7.6bn |
| Adjusted operating EBITDA | US$1.53–1.60bn |
| Comparable currency-neutral sales growth | 2–4% |
| Comparable currency-neutral adj. EBITDA growth | 4–8% |
| FX | ~+1% sales; ~+2% EBITDA |
| H2 2026 implied sales growth | ~0–4% |
| Discontinued operations | ~US$3.2bn sales; ~US$520m adj. EBITDA |
Consensus growth expectations
Q2 2026 commentary (Zacks Rank #5) indicates downward estimate revisions after the recast, though part of the apparent "miss" (US$0.82 vs. US$1.14) reflects consensus that had not yet been rebased for discontinued operations.
Bull case
-
Pure-play re-rating. The continuing business delivered a 21.8% adjusted EBITDA margin in H1 2026 with volume-led 4% organic growth; with Food Ingredients sold at ~10x EBITDA, the residual company trades at a discount to peers despite a similar mix.
-
Accretive capital return. A US$2.5bn buyback equates to roughly an eighth of the market cap; funded mainly by ~US$3.8bn of net CVC proceeds while still reducing debt by >US$1bn.
-
Antitrust de-risking. The DOJ closed its investigation in February 2026 and IFF has already settled a substantial portion of US civil claims for only US$26m.
Bear case
-
Shrinking earnings base and stranded costs. Continuing EBITDA of ~US$1.57bn (midpoint) is far below the FY2024 total (US$2.2bn); ~US$100m of stranded costs and dis-synergies must be eliminated, and EPS dilution will precede buyback accretion.
-
Regulatory fines. EC, CMA, COMCO, Mexico, India (two cases) and Singapore remain open; EC cartel fines can reach up to 10% of global turnover, and IFF is already booking provisions (Q2 2026 regulatory costs US$71m).
-
Margin squeeze in H2 2026 and Scent fragility. Input inflation with pricing lagging into 2027, Middle East exposure in Fine Fragrance, and a 150bp Scent margin decline in FY2025 could cap upside.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing |
|---|---|
| Q3 2026 results and FY2026 guidance reaffirmation | ~4–5 Nov 2026 |
| Execution of US$500m ASR | H2 2026 |
| SuanNutra and CitraSource closings | By end-2026 |
| FY2026 results and first full-year continuing-ops outlook | ~Feb 2027 |
| EC / CMA / COMCO antitrust decisions or settlements | Uncertain |
| CVC regulatory approvals and closing | By end-Q2 2027 |
| Post-close US$2.0bn buyback and >US$1bn debt paydown | H2 2027 |
| Possible investor day with medium-term targets for the new IFF | Unconfirmed |
| Icahn cooperation agreement expiry / renewal | Around 2027 AGM notice deadline |
| Further rating actions (S&P, Moody's) | Following FI close |
Analyst verdict
IFF is approaching the end of a five-year unwind of the complexity and debt it assumed through the Frutarom acquisition and the DuPont Nutrition & Biosciences merger. The evidence that the turnaround is real is now reasonably strong: under Erik Fyrwald the company met its 2025 commitments, delivered 7% comparable currency-neutral EBITDA growth on modest top-line growth, cut net leverage from 3.8x to 2.5x, earned an S&P upgrade to BBB, and — most importantly — monetised its weakest segment at a respectable ~10x EBITDA. What remains is a three-segment company with ~US$7.5bn of sales, a margin profile in the low 20s and genuine scientific differentiation in enzymes, cultures and probiotics that none of its F&F peers fully replicates.
The equity, however, still prices in meaningful doubt. At roughly 12x total-company EBITDA and ~18–19x adjusted earnings excluding amortisation, IFF trades at a clear discount to the best-in-class flavour-and-fragrance houses. That discount is defensible for now: GAAP earnings are depressed by recurring "non-recurring" costs, goodwill still dwarfs tangible capital, the fragrance cartel investigations in Europe, the UK, Switzerland, Mexico, India and Singapore could yield material fines, and the CVC transaction will not close until mid-2027, leaving the US$2.0bn post-close buyback contingent.
On balance, the risk-reward skews modestly positive for investors with a 12–24-month horizon. The thesis hinges on three verifiable milestones: sustained 3–5% organic growth in the continuing segments through the H2 2026 cost squeeze; on-time closing of the CVC deal with stranded costs removed on the promised schedule; and an antitrust outcome in the EC process that is financially containable. Delivery on all three would justify a narrowing of the valuation gap to peers; a large EC fine or a slip in Scent margins would leave IFF as a cheaper but structurally lower-quality alternative to Givaudan. Monitor Q3 2026 results and ASR execution as the next proof points.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure in role | Prior roles | Education | Age |
|---|---|---|---|---|---|
J. Erik Fyrwald | Chief Executive Officer; Director | Since 6 Feb 2024 | CEO Syngenta Group (2016–2024); CEO Univar Solutions (2012–2016); Chairman & CEO Nalco (2008–2011); President Ecolab; 27 years at DuPont incl. VP & GM Nutrition & Health; director of Eli Lilly since 2005 | BS Chemical Engineering, University of Delaware; Harvard AMP | 66 |
Michael DeVeau | EVP & Chief Financial Officer | Since 1 Jan 2025 | IFF since 2009: SVP Corporate Finance & IR; Divisional CFO Scent; Chief Strategy Officer; previously PepsiCo (IR, finance, corp. dev.) and Citigroup equity research | BA Fordham; INSEAD Global Executive Leadership Program | — |
Leticia Gonçalves Lourenço | President, Health & Biosciences | Since 1 Mar 2025 | ADM President, Precision Fermentation & ADM Ventures; senior roles at Bayer and Monsanto; director of Emerson Electric | — | — |
Andres (Andy) Muller | President, Food Ingredients | Since 2025 | — | — | — |
Ana Paula Teles de Mendonça | President, Scent | — | — | — | — |
Yuvraj Arora | Named executive officer (role per 2026 proxy; believed President, Taste — confirm) | — | — | — | — |
Deborah Borg | Section 16 officer (believed EVP, Chief People & Culture Officer — confirm) | — | — | — | — |
Brynn Samson | SVP, Chief Compliance Officer & Corporate Secretary | — | — | — | — |
Michael Bender | Head of Investor Relations | — | — | — | — |
Directors' Remuneration
| Item | Value | Source |
|---|---|---|
CEO FY2025 annualised total compensation | US$15,002,866 | 2026 Proxy, pay-ratio section |
CEO FY2024 annualised total compensation (incl. one-time sign-on awards) | US$24,248,498 | 2025 Proxy |
Median employee FY2025 total compensation | US$62,828 | 2026 Proxy |
CEO pay ratio FY2025 | 239:1 | 2026 Proxy |
CEO pay ratio FY2024 | 381:1 (231:1 excluding sign-on and relocation) | 2025 Proxy |
CEO sign-on awards (granted 1 Mar 2024) | RSUs US$4,268,250 (3-yr cliff) + PSUs US$4,914,250 (TSR/price-hurdle based) | 2025 Proxy |
CEO deferral | Deferred US$2,908,800 FY2024 annual incentive into the non-qualified plan | 2026 Proxy |
Board of Directors
| Director | Primary occupation | Joined | Age (3 Mar 2026) | Independent | Committees (post-AGM 2026) |
|---|---|---|---|---|---|
Kevin O'Byrne | Former CFO & Director, J Sainsbury plc; Chair of Centrica plc | 2023 | 61 | Yes | Non-executive Chair; Governance & Corporate Responsibility |
J. Erik Fyrwald | CEO, IFF | 2024 | 66 | No | — |
Virginia C. Drosos | Former CEO, Signet Jewelers; ex-P&G Group President Global Beauty | 2025 | 63 | Yes | Chair, Human Capital & Compensation; Innovation |
Paul J. Fribourg | Chairman & CEO, Continental Grain; director Loews, Estée Lauder, Syngenta Group | 2025 | 72 | Yes | Audit |
Brett Icahn | Investor and portfolio manager, Icahn Capital (Icahn designee) | 2025 | 46 | Yes | Audit |
Cynthia T. Jamison | Former CFO AquaSpy; Chair of Darden Restaurants; CPA | 2025 | 66 | Yes | Chair, Audit; Governance & Corporate Responsibility |
Mehmood Khan | CEO, Hevolution Foundation; ex-PepsiCo Vice Chairman & CSO | 2025 | 67 | Yes | Chair, Innovation; Governance & Corporate Responsibility |
Jesus B. Mantas | Retired senior executive, IBM Consulting; director Biogen | 2025 | 57 | Yes | Audit; Human Capital & Compensation; Innovation |
Richard Mulligan | Mallinckrodt Professor of Genetics, Emeritus, Harvard Medical School (mutually agreed Icahn-cooperation director) | 2025 | 71 | Yes | Innovation |
Dawn C. Willoughby | Former EVP & COO, The Clorox Company; director J.M. Smucker, TE Connectivity | 2023 | 56 | Yes | Chair, Governance & Corporate Responsibility; Human Capital & Compensation |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
Feb 2024 | Fyrwald succeeds Clyburn as CEO | Board sought turnaround leadership |
10 Dec 2024 (announced) | DeVeau named CFO effective 1 Jan 2025; Glenn Richter retires | Internal succession |
20 Feb 2025 | ELT aligned with new operating model; Simon Herriott (H&B) steps down after 21 years; Gonçalves Lourenço hired | Business-led operating model |
May 2025 | O'Byrne becomes Chair; Ferguson, Davidson, Gold leave | Board refresh |
Oct 2025 | Intrieri and Paláu-Hernández replaced by Brett Icahn and Mulligan | Icahn agreement mechanics |
Apr 2026 | Ferraro, Costa, Boor leave; board reduced to 10 | Further refresh |
Major Shareholders
| Holder category | Detail |
|---|---|
Top 10 institutional holders | 5%+ holders are listed on p.28 of the 2026 Proxy |
Insider ownership | Individually below 1%; CEO direct holding ≈0.03–0.035% (third-party data). Directors and executive officers as a group: NA |
Notable new holder | Heartland Mid Cap Value Fund described IFF as a new "deep value" holding (2026) |
Competitive Landscape
Key Competitors
| Competitor | HQ | Segments where it competes with IFF | Approx. latest annual revenue | Notes |
|---|---|---|---|---|
Givaudan | Switzerland | Taste, Scent | — | Industry leader; premium valuation |
DSM-Firmenich | Switzerland/Netherlands | Taste, Scent, H&B (nutrition, enzymes) | ~€12.8bn (FY2024 group) | Formed 2023; restructuring Animal Nutrition & Health |
Symrise | Germany | Taste, Scent, pet food | ~€5.0bn (FY2024) | Strong in aroma molecules and pet food |
Kerry Group | Ireland | Taste (taste & nutrition systems), Food Ingredients | ~€7bn (FY2024) | Integrated taste/nutrition systems |
Novonesis (Novozymes + Chr. Hansen) | Denmark | H&B (enzymes, cultures, probiotics) | ~€4bn (FY2024) | Primary biosolutions rival |
Takasago | Japan | Taste, Scent, aroma chemicals | — | Strong in Asia; menthol |
Mane | France (private) | Taste, Scent | NA (private) | Family-owned; agile mid-market |
Robertet | France | Scent, naturals, Taste | — | Naturals specialist |
Sensient Technologies | USA | Taste, colours | — | Colours leadership |
ADM (Nutrition) | USA | Taste, Food Ingredients, Health | — | Flavours (Wild) and proteins |
Tate & Lyle | UK | Food Ingredients (texturants, sweeteners) | — | Competes with divested FI business |
AB Enzymes / BASF / dsm-firmenich | Germany/NL | H&B enzymes | — | Enzyme competition |
Competitor Detail
| Metric | IFF (FY2025, reported) |
|---|---|
Revenue | US$10.89bn |
Organic / comparable growth (%) | 2 |
Adjusted EBITDA margin (%) | 19.2 (continuing H1 2026: 21.8) |
R&D intensity (% of sales) | 6.4 |



